Cargando…

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

BACKGROUND: Treatments of non-small-cell lung cancer (NSCLC)—particularly of the squamous subtype—are limited. In this article, we describe the immunomodulatory environment in NSCLC and the potential for therapeutic targeting of the immune system through cytotoxic T-lymphocyte antigen 4 (CTLA-4) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zielinski, C., Knapp, S., Mascaux, C., Hirsch, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629900/ https://www.ncbi.nlm.nih.gov/pubmed/23393121 http://dx.doi.org/10.1093/annonc/mds647

Ejemplares similares

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
por: Hallqvist, Andreas, et al.
Publicado: (2020)

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
por: Lau, Asa P. Y., et al.
Publicado: (2023)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
por: Hastings, K, et al.
Publicado: (2019)

Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
por: Wu, Qiuyu, et al.
Publicado: (2023)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
por: Paglialunga, Luca, et al.
Publicado: (2016)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer
por: Huang, Qingyuan, et al.
Publicado: (2022)

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
por: Jiang, Zedong, et al.
Publicado: (2021)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
por: Harel, Michal, et al.
Publicado: (2022)

Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non–small cell lung cancer
por: Mao, Wenjun, et al.
Publicado: (2022)

Reply: K-Ras: a prognostic factor for survival in non-small cell lung cancer
por: Mascaux, C
Publicado: (2006)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
por: Boesch, Maximilian, et al.
Publicado: (2021)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
por: Karachaliou, Niki, et al.
Publicado: (2018)

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
por: Zhang, Feiyu, et al.
Publicado: (2021)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

The future of immune checkpoint combinations with tumor-targeted small molecule drugs
por: Sceneay, Jaclyn, et al.
Publicado: (2021)

Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate
por: Lo, Chen-Fu, et al.
Publicado: (2022)

Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
por: Chi, Alexander, et al.
Publicado: (2021)

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer
por: Han, Shuai, et al.
Publicado: (2023)

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
por: Dora, David, et al.
Publicado: (2020)

Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA
por: Pan, Jing, et al.
Publicado: (2021)

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
por: Ravi, Arvind, et al.
Publicado: (2023)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
por: Georganaki, Maria, et al.
Publicado: (2018)

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients
por: Saruwatari, Koichi, et al.
Publicado: (2019)

Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer
por: Su, Chunxia, et al.
Publicado: (2021)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_arp7bn0n7hnppdam6u50bpqbpo